Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $50 price target on the stock.
November 27, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has reaffirmed an Overweight rating for Mirum Pharmaceuticals with a steady price target of $50.
The reiteration of an Overweight rating by a reputable analyst typically signals confidence in the company's future performance and may positively influence investor sentiment. The maintained price target of $50 suggests a potential upside from the current trading price, assuming the market aligns with the analyst's valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100